| Financial year | Sales, PKR billion | Profit after tax, PKR million | Net profit margin |
|---|---|---|---|
| 2022 | 2.453 | -22.158 | -0.90% |
| 2023 | 3.025 | 113.899 | 3.77% |
| 2024 | 1.502 | 101.203 | 6.74% |
| 2025 | 1.720 | -25.950 | -1.51% |
Source note: Figures are based on the Pakistan Stock Exchange’s GLPL financial summary, which states that its comparative data may be standardised and that issuer reports remain the definitive “as reported” source.
Look carefully. Sales collapsed between 2023 and 2024, recovered somewhat in 2025 and yet the company fell back into a loss. That is evidence of a troubled operating picture. It is not evidence that a particular Pakistani competitor displaced Gillette, because proving that argument would require credible category-level market-share data, pricing analysis, channel penetration and evidence of consumer substitution.
Saying “nobody uses Treet, everybody uses Gillette” is anecdotal. Saying “Tibbet destroyed Safeguard in rural Pakistan” is also anecdotal unless the person presents measurable market data. A Pakistani patriot should demand better evidence, not lower the standard of proof merely because the conclusion sounds good for Pakistan.
I want Pakistani manufacturing to win. Precisely because I want it to win, I refuse to issue it imaginary medals.
What Actually Happened to the Famous “MNC Exit List”?
This is where the anti-Pakistan doom narrative also starts falling apart. A viral list repeatedly grouped P&G, Sanofi, Shell, Bayer, Telenor, Pfizer, TotalEnergies, Eli Lilly, Microsoft and Careem together under one emotionally explosive word: exited.
Except corporate transactions are not school attendance sheets. “Present” and “absent” are insufficient categories.
